Costs and benefits of early response in the Ebola virus disease outbreak in Sierra Leone by Kellerborg, K. (Klas) et al.
Kellerborg et al. Cost Eff Resour Alloc           (2020) 18:13  
https://doi.org/10.1186/s12962-020-00207-x
RESEARCH
Costs and benefits of early response 
in the Ebola virus disease outbreak in Sierra 
Leone
Klas Kellerborg* , Werner Brouwer and Pieter van Baal
Abstract 
Background: The 2014–2016 Ebola virus disease (EVD) outbreak in West Africa was the largest EVD outbreak 
recorded, which has triggered calls for investments that would facilitate an even earlier response. This study aims to 
estimate the costs and health effects of earlier interventions in Sierra Leone.
Methods: A deterministic and a stochastic compartment model describing the EVD outbreak was estimated using 
a variety of data sources. Costs and Disability-Adjusted Life Years were used to estimate and compare scenarios of 
earlier interventions.
Results: Four weeks earlier interventions would have averted 10,257 (IQR 4353–18,813) cases and 8835 (IQR 3766–
16,316) deaths. This implies 456 (IQR 194–841) thousand DALYs and 203 (IQR 87–374) million $US saved. The greatest 
losses occurred outside the healthcare sector.
Conclusions: Earlier response in an Ebola outbreak saves lives and costs. Investments in healthcare system facilitat-
ing such responses are needed and can offer good value for money.
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Background
The West African Ebola virus disease (EVD) outbreak 
was the largest EVD outbreak since the virus was discov-
ered. The outbreak mainly affected Guinea, Liberia, and 
Sierra Leone which together reported 28,616 confirmed, 
probable and suspected cases and 11,310 deaths [1]. Dis-
ruptive effects also affected health-seeking behavior and 
healthcare delivery [2–6]. As the case counts grew, the 
outbreak drew international attention. In August 2014 
the WHO published the Roadmap for response, outlining 
three phases of response initiatives to combat the out-
break [7]. In October 2014, during the first phase, the UN 
Mission for Ebola Emergency Response (UNMEER) was 
launched [8]. UNMEER had several aims: that 70 percent 
of cases would be isolated and that 70 percent of the bur-
ials would be conducted in a safe manner. Approximately 
2 months after the UNMEER initiated interventions were 
implemented, the national weekly case counts decreased 
[9]. Although the response operations seemed to effec-
tively control the outbreak, critical voices raised an issue 
with the timeliness of the responses. Both the recognition 
of the outbreak and the implementation of the interven-
tions came too late according to critics [10–12]. The EVD 
epidemic highlighted the importance of surveillance sys-
tems for early detection as the virus remained undetected 
for the first 3 months of the EVD outbreak [12–15].
Previous studies have estimated the effectiveness of 
various interventions, both real and hypothetical aimed 
at mitigating the outbreak [16–27]. In an early stage 
of the outbreak Rivers et  al. explored several different 
interventions and found that those would not effectively 
control the outbreak [19]. Kucharski et  al. estimated 
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the number of averted cases due to the introduction of 
additional hospital beds in Sierra Leone, and found that 
the increased capacity averted approximately 56,000 
cases [26]. Barbarossa et  al. estimated the effect of the 
response efforts on the number of cases and concluded 
that a 5-week earlier implementation would halve the 
outbreak size [27]. Other studies have investigated the 
health effects of the EVD outbreak caused by disruption 
of the health care system [28–30]. Apart from interven-
tions, the economic effect of the outbreak has also been 
studied [31–33]. Bartsch et al. performed a cost of illness 
study comprising EVD treatment costs and productiv-
ity losses, suggesting that the total cost of the epidemic 
in Sierra Leone was approximately 30 million US$ [31]. 
Additionally, Kirigia et  al. estimated future production 
losses due to EVD mortality to approximately 60 million 
international$ in Sierra Leone [32]. Finally, The World 
Bank estimated the outbreaks’ impact on the GDP of the 
outbreak-affected economies affected to be 2.8 billion 
US$, where Sierra Leone was most affected and incurred 
a loss of 1.9 billion US$ [33].
Although studies have investigated the effects of the 
outbreak in different intervention scenarios little work 
has been performed on the combination of potential 
health benefits and cost savings of earlier interventions. 
In this paper, we focus on providing estimates of costs 
and health consequences of the outbreak and the poten-
tial benefits of an earlier response. Moreover, this study 
also provides relevant input for discussions on more 
general investments to strengthen relatively weak health 
systems [32]. To enable comparability, we measure health 
losses in Disability Adjusted Life Years (DALY) and take 
into account the costs associated with an outbreak both 
within and outside the healthcare sector. DALYs are a 
summary measure of health that comprise both length 
and quality of life [34], being widely used in cost-effec-
tiveness studies which facilitates comparison with similar 
studies. Furthermore, DALYs lost because of early death 
are closely linked to productivity losses as health facili-
tates productivity. Given that the EVD outbreak affects 
people in their working age/productive years, an exclu-
sive focus on the costs incurred within the health system 
would result in an incomplete picture of the impact of 
earlier response [35].
Methods
To estimate the incremental health benefits and poten-
tial costs of earlier interventions in the scenario of the 
EVD outbreak in Sierra Leone we used a compartment 
model to describe the transmission under the baseline 
scenario- the actual outbreak -, and several counter-
factual scenarios. The counterfactual scenarios mimic 
earlier interventions varying from 1 day earlier up to 4 
weeks earlier. We attached treatment costs and produc-
tion losses to the transmission model compartments. We 
also attached disability weights to the compartments, 
from which DALYs were calculated. The sum of costs and 
DALYs were calculated under the baseline and the two 
counterfactual scenarios. We assessed the uncertainty of 
our results with respect to the uncertainty surrounding 
input parameters and carried out a sensitivity analysis for 
several key parameters.
Transmission model
To explore the potential benefits of earlier response we 
used an extended SEIR compartment model, based on 
the model of Kucharski et  al. [26]. The model aims at 
describing the natural course of the disease and incorpo-
rating setting specific context such as hospitalization in 
either holding centers or treatment centers, which is then 
run on a district level. Figure 1 depicts the model sche-
matics: upon contracting the virus the individual leaves 
the Susceptible compartment (S) and enters the latent 
compartment (E). From the E compartment the individu-
als’ transition to the infectious compartment (I). When 
entering the I compartment, the individuals are infectious 
to others. As not all cases are assumed to be reported, the 
I compartment is differentiated in reported cases and 
cases not being reported. We assumed that the infection 
rate is the same for both I compartments and from there 
on infected individuals may die or recover from the EVD. 
If the infected individuals are reported then, if district 
beds are available, they are hospitalized. During hospital-
ization, they are assumed not to be infectious to others. 
During the outbreak, facilities with different functions 
existed such as holding centers and treatment centers. In 
our model we treated the different facilities as the same, 
assuming that the fatality rates did not differ. Within each 
district, homogenous mixing was assumed and no spatial 
Fig. 1 Compartment model schematic. Solid lines indicate transition 
paths; dashed lines indicate transmission routes. With the following 
compartments, Susceptible (S), Exposed (E), Infectious and reported 
 (IR), Infectious and not reported  (IU), Hospitalized (H), Dead (D) and 
lastly Recovered (R)
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interaction was accounted for. The whole population was 
assumed to be susceptible. Due to the small number of 
reported cases we excluded the Bonthe district.
The transmission rate and parameters capturing the 
effect of the interventions implemented during the out-
break were fitted to the reported number of cases by 
weighted least squares, from the WHO’s situation reports 
[1]. The parameters were fitted separately for each dis-
trict, to reduce identifiability issues we derived some 
parameter values from other studies (see Additional files 
1 and 2 for more information). In Table 1 the parameters 
used in the model that are not district dependent are 
presented.
We allowed the infection rate to vary to accommodate 
different outbreak paces between districts. After the 1st 
of October 2014, the date of the UNMEER implementa-
tions [37], we introduced the effect of interventions in 
the model. We allowed the effect of the interventions to 
vary between districts. As the weekly number of reported 
cases declined at different speeds we did not force a lin-
ear decrease on the effect of the interventions.
Translating morbidity and mortality effects into DALYs 
and costs
The health loss due to EVD expressed in DALYs is the 
sum of health losses during an illness and the health 
lost because of an early death. To estimate health losses 
we attached disability weights from the Global Burden 
of Disease (GBD) study to the relevant compartments 
[38]. Health losses because of early death were assumed 
to be equal to Health Adjusted Life Expectancy (HALE) 
estimates for Sierra Leone from GBD. To estimate the 
remaining HALE for each case the observed age distribu-
tion of reported cases was applied to the final outbreak 
size [23]. The full societal costs as a consequence of EVD 
include not only direct costs such as treatment costs for 
EVD but also indirect costs such as production losses, 
due to sickness and death at a young age. As in Bartsch 
et  al. two treatment options were included: support-
ive and extensive supportive care [31]. Supportive care 
consists of paracetamol, oral rehydration salts, metoclo-
pramide for nausea. Extensive care adds morphine for 
pain, diazepam for convulsions, Ringer’s lactate against 
shock and broad-spectrum antibiotics. As no proportion 
of the severity of cases was available a random number 
was drawn from a uniform distribution from 0 and 1 for 
each run representing the proportion of cases receiv-
ing supportive care. For treatment costs, the costs esti-
mated by Bartsch et  al. were used [31]. For reasons of 
international comparability, we calculated the produc-
tion losses according to the Human capital method [39]. 
GDP per capita was used as a proxy for annual produc-
tion losses and was multiplied by the HALE lost for early 
deaths to estimate lifetime production losses. An implicit 
assumption here is that life years spent in poor health 
do not result in productivity gains in our estimation. For 
recoveries, the productivity loss from Bartsch et  al. due 
to absenteeism was used [31]. Costs are all expressed in 
2014 US dollars (Table 2).
Interventions and counterfactual scenarios
To explore the potential benefits and costs of timely 
interventions we created counterfactual scenarios of 
earlier interventions. In our initial analysis we compare 
Table 1 Parameters estimated and fixed with their respective source
Parameter Description Value References
a2 Maximum value of transmission rate Estimated See Additional files 1 and 2
a1 Slope of transmission rate parameter Estimated
Midpoint of transmission rate parameter Estimated
b1 Slope of intervention rate parameter Estimated
Midpoint of intervention rate parameter Estimated
1/σ Latent period 10.4 days [36]
1/γCR Time to recovery in the community 11.7 days [36]
1/γCD Time to death in the community 6.8 days [36]
1/γHR Discharge rate 11.6 days [36]
1/γHD Time to death for hospitalized 5.2 days [36]
Proportion reported 83% [36]
1/ω Time to notification 4.8 days [36]
1/η Hospitalization rate 4.6–1.3 days See Additional files 1 and 2
δC Fatality rate in the community 91.9% [36]
δH Fatality rate for hospitalized 60.3% [36]
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the baseline scenario—interventions as they were imple-
mented by the UNMEER—to a counterfactual scenario 
of interventions taking place 4 weeks earlier. We then 
continued to investigate the effect on health and costs 
with interventions taking place between the baseline 
scenario and 4 weeks earlier in steps of 1 day. The coun-
terfactual scenarios were modeled by moving the time of 
interventions in the transmission model 4 weeks earlier. 
This affected the transmission parameter and also the 
hospitalization rate and the case fatality rates for those 
hospitalized.
Assessment of uncertainties of transmission models
We assessed the uncertainty of our outcomes by taking 
into account the uncertainty around the input param-
eters of the compartment model and our health and 
cost estimates. In our main scenario of a 4 week ear-
lier counterfactual we implemented a stochastic model 
using the tau-leaping approximation of the Gillespie’s 
algorithm with a time step of 0.01  days [41, 42]. The 
approximation treats individuals as discrete units and 
translates the rates into probabilities allowing for sto-
chasticity in all transitions. We performed several 
univariate sensitivity analysis to explore the impact of 
key input parameters on our outcomes. We varied the 
proportion of underreporting by ten percentage points, 
the time for cases to be reported, the time to hospitali-
zation and the timing of interventions by 1 day each.
Results
Model fit
Figure  2 shows the fit of the reported cases of the 
models median and interquartile range by district 
and nationally against the reported number of weekly 
cases. Our model estimated 8609 (3882–8609) reported 
cases which is a bit lower than the number actually of 
reported cases, with the largest discrepancy being in 
the Western Area Rural district reported cases. Distinct 
temporal differences between districts can be observed 
such as in Kailahun and Kenema, which experienced 
a peak of reported cases earlier than other districts. 
These two districts displayed a decrease in cases before 
the implementation of the UNMEER interventions. For 
the fitted parameter values per district and results per 
district, see Additional files 1 and 2.
Table 2 Costs and health parameters included, mean and 95% confidence interval in brackets
By age groups and costs groups. Expressed in 2014 $US
Cost group Age group: References
< 15 years 15–44 years ≥ 45 years
Supportive care
 Patient recovers 431 (413–450) 446 (428–466) 447 (428–464) [31]
 Patient dies 178 (163–195) 185 (169–202) 185 (168–202) [31]
Extensive supportive care
 Patient recovers 598 (576–622) 830 (800–862) 830 (801–859) [31]
 Patient dies 238 (217–259) 321 (292–351) 322 (291–351) [31]
Personnel costs
 Patient recovers 59 (57–61) 59 (57–61) 59 (57–61) [31]
 Patient dies 21 (19–23) 21 (19–23) 21 (19–23) [31]
Productivity losses due to
 Absenteeism during illness episode 23 (22–24) 23 (22–24) 23 (22–24) [31]
 Mortality 42 747.2
(12 355.9–128 273.4)
29 640
(7 599.2–90 040.3)
13 227.5
(2 934.1–42 393.5)
Calculated using the 
wealth distribution 
[40]
Disability weights
 Acute phase of illness 0.133 (0.088–0.19) [38]
 Post-sequelae 0.219 (0.148–0.308) [38]
 Mortality, HALE (range) 51.3 (48.11–53.51) 34 (24.76–43.84) 13.92 (7.32–21.38) [38]
Duration of illness
 Acute phase, recover 15.1 (14.6–15.6) days [38]
 Acute phase, death 8.2 (7.9–8.4) [38]
 Post-sequelae 0.75 years (0.417–1.135) [38]
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Effect of earlier interventions
Districts with a large number of cases and exponential 
growth showed the greatest savings of costs and health. 
In a large number of the districts, the time of interven-
tions and the decrease of cases correlated well. Four 
weeks earlier interventions resulted in cost savings and 
health gains compared to the baseline scenario. The 
savings in both costs and health were largely due to the 
averted mortality as seen in Table  3 where results are 
shown based on outcomes of the stochastic model. Our 
result suggests that interventions implemented 4 weeks 
earlier would have halved both the costs and the health 
losses. Results by district are available in Additional file 2.
Figure 3 shows the incremental benefits of interven-
ing earlier, from 1 day to 8 weeks, using the determinis-
tic model. At 4 weeks, the same number of days earlier 
as in our main scenario, the estimated benefits gained 
from earlier interventions were estimated to 182 mil-
lion US$. One week later would have averted 32 million 
US$ and 47 thousand DALYs less. Conversely, imple-
mentation 1 week earlier would yield an additional 25 
million US$ and 38 thousand DALYs gained. Beyond 
our main scenario intervention date, the incremental 
benefits are diminishing in returns. Note that the aver-
age outcomes of the stochastic model as displayed in 
Table  3 differ from the outcomes produced with the 
deterministic model given the non-linearities in the 
model. Therefore, the numbers in Fig.  3 differ some-
what of those reported in Table 3.
From the univariate sensitivity analysis, presented 
in Fig. 4, we found that the parameter with the greatest 
impact is time to hospitalization. Reducing the time of 
intervention by 1 day would avoid 500 cases and reduc-
ing the time to hospitalization by 1 day would avoid 
3671 cases, for the time to notification the estimate is 
668 cases avoided. When decreasing the underreport-
ing by one percentage point it showed a smaller effect 
of 28 cases avoided. The relative decrease in values is 
Fig. 2 Stochastic model fit on the national and district level. Solid line shows the median number of reported cases of 1500 model runs. Blue areas 
are the interquartile range. Reported cases by the WHO patient database are given as black dots. Vertical line shows the date of implementation of 
interventions
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substantially larger for the time to notification and hospi-
talization than for the timing of interventions.
Discussion
This paper estimated the costs and health losses of 
the EVD outbreak in Sierra Leone from a societal per-
spective and provided estimates of the benefits from 
earlier interventions. The results suggest that timely 
interventions can reduce the loss of health and drasti-
cally reduce the economic impact of outbreaks. This 
emphasizes the importance of timely interventions. The 
largest contribution to the total cost in all scenarios 
was productivity losses, which arise from mortality at 
a young age. In our deterministic analysis, we showed 
that much benefit may be gained by even earlier inter-
ventions, albeit at a diminishing rate.
Before we highlight some implications of our find-
ings, we note some limitations of this study. Impor-
tantly, several assumptions had to be made due to 
lacking data or poor quality data. Models previously 
used for EVD (e.g. [43]), allowed for explicit modeling 
of several transmission routes. To avoid fitting several 
transmission parameters and identifiability problems 
we did not model funeral transmissions or hospital 
transmissions explicitly. Evidently, funeral transmis-
sions were an important driver of the outbreak and a 
facilitator of super-spreading events [44]. We assumed 
in our model that infectiousness remains the same 
throughout the symptomatic period, which may not be 
Table 3 Incremental results of scenarios compared to baseline
Median and interquartile range based on outcomes produced with the stochastic model
4 weeks earlier (IQR)
Cases averted 10,257
(4353–18,813)
Deaths averted 8835
(3766–16,316)
DALY s averted (thousand) 455.8
(194.1–841.11)
DALYs averted by preventing Ebola episodes (time spent with Ebola times number of cases) 0.23
(0.1–0.41)
DALYs averted by preventing premature deaths (deaths averted times remaining health adjusted life expectancy) 455.57
(194–840.7)
Costs saved (million US$) 202.82
(87.42–373.86)
Within health care sector: Ebola treatment 1.77
(0.86–2.52)
Outside healthcare sector: productivity losses 201.05
(86.56–371.34)
Fig. 3 Benefits of earlier interventions in one-day increments based on outcomes produced with the deterministic model. Left-hand panel shows 
the costs saved, right-hand panel shows the DALYs gained
Page 7 of 9Kellerborg et al. Cost Eff Resour Alloc           (2020) 18:13  
fully accurate and may rather be increasing closer to 
death [45]. The implication of this assumption is that 
we may have underestimated the benefits of earlier 
interventions, as the infected are hospitalized sooner 
after interventions and transmission rates are lower 
in hospitalized settings. Our model assumed homog-
enous mixing within compartments, meaning that all 
individuals have the same probability of contact. In 
reality, this assumption may not hold as individuals 
mix within their respective contact network primarily 
which may limit spread. For the current purpose, we 
did not include transmission caused by district interac-
tion of individuals in different districts. This may again 
have underestimated the impact of the health gained 
and costs saved due to earlier interventions, as earlier 
interventions may prevent infected individuals from 
spreading the virus to other districts. Underreporting 
is assumed to occur during an EVD outbreak, however, 
few studies have provided concrete evidence of the pro-
portion of underreporting. We, therefore, assumed a 
moderate estimate (compared to estimates by the CDC) 
whereby for each reported case, 2.5 cases were not 
reported [46]. As uncertainty exists regarding the inter-
ventions performed, assumptions had to be made to 
calculate the effects of the interventions. We assumed 
that the decline in transmission after the 1st of October 
2014 was solely caused by the interventions, and not 
taking into account independent behavior which was 
not due to for example information campaigns or com-
munity leader engagement. We did not differentiate 
between different types of interventions as this was not 
our aim, we were interested in the total effect. However, 
in our sensitivity analysis we saw that time to hospitali-
zation proved very important in limiting the number of 
new cases. Another limitation is in the use of a single 
date to account for the interventions performed by the 
UNMEER. This assumes that the interventions and the 
effects were more homogenous than in reality. Our esti-
mate of the production losses is much larger than that 
of the cost of illness study by Bartsch et  al. [31]. Our 
approach estimated the years of productivity lost due to 
EVD mortality as the HALE lost multiplied by average 
annual GDP of Sierra Leone and also included the latest 
data on reported cases. The total estimated economic 
loss in the baseline scenario mounted to 635 million 
US$. This is a smaller estimate than previously esti-
mated by the World Bank (WB). The difference is due 
to the choice of approach, as the WB applied a macro-
economic level to determine the GDP loss in short and 
medium term. Our focus remained on individual costs 
Fig. 4 Sensitivity analysis of key parameters based on outcomes produced with the deterministic model. The parameters of interest are located on 
the y-axis and difference in cases compared to the baseline scenario on the x-axis. Estimates are on the left-hand side varied with ten percentage 
points less for the percentage of underreported, 1 day less for the time to notification, time to hospitalization and time of intervention. Right-hand 
side shows the difference in cases from an increase of the same amounts for the same parameter values
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to the health care system and the long-term production 
losses arising from deaths. An underexplored issue here 
is which approach is most suitable to estimate these 
productivity costs. In economic evaluations sometimes 
the human capital approach is replaced with the fric-
tion cost method, under the assumption that replace-
ment of ill or deceased workers (through a reshuffling 
of labor or employing previously unemployed) will help 
to reduce total productivity costs (e.g. Brouwer et  al. 
[47]). In countries and circumstances like the outbreak 
studied, it is unclear whether similar mechanisms exist 
and would lower productivity cost estimates. If we 
would assume this to be the case and production levels 
would be restored after 1 or 5  years, production costs 
would be estimated to be 7.07 (3.08–13.08) and 34.14 
(14.61–63.29) million US$ respectively.
Conclusions
The consequences of this outbreak proved devastating. 
However, it has been shown that EVD can be stopped 
in an early phase. Illustrated by the example of Nigeria, 
where quick response and actions managed to halt the 
outbreak containing the number of cases to 19 with seven 
deaths [48], however, this occurred at a later phase when 
the outbreak was known and the responders ready. Swift 
detection and isolation saved not only lives but was done 
at a cost of approximately 13 million US$ using the exist-
ing Polio surveillance infrastructure. This cost estimate is 
approximately 6 percent of the cost savings with interven-
tions 4 weeks earlier in Sierra Leone. This study does not 
provide guidance on which preventive measures are best 
suited to preventing or limiting outbreaks. However, we 
do know that the virus was first discovered after several 
months of circulating in the population which advocates 
for systems capable of detecting emerging viruses before 
they spread more widely. The most important result 
from this study is that is considerable gains to be made 
from timely interventions, and that the losses primar-
ily occurred outside the healthcare sector. To improve 
the capabilities for handling the next outbreak prefer-
ably before a new outbreak occurs. Timeliness is not only 
important in intervening, but also in the context of clear 
policy action.
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